Based on the ACADIA Pharmaceuticals Inc stock forecast from 7 analysts, the average analyst target price for ACADIA Pharmaceuticals Inc is USD 26.96 over the next 12 months. ACADIA Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ACADIA Pharmaceuticals Inc is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, ACADIA Pharmaceuticals Inc’s stock price was USD 16.87. ACADIA Pharmaceuticals Inc’s stock price has changed by -2.26% over the past week, +3.05% over the past month and -46.27% over the last year.
No recent analyst target price found for ACADIA Pharmaceuticals Inc
No recent average analyst rating found for ACADIA Pharmaceuticals Inc
Company Overview ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Read Less
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavans...Read More
Frequently Asked Questions About ACADIA Pharmaceuticals Inc (ACAD) Stock
Based on ratings from 7 analysts ACADIA Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ACAD's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ACAD is USD 26.96 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 20.
ACAD stock's Price/Earning ratio is 22.13.
Our analysis grades ACAD stock's Price / Earning ratio at F. This means that ACAD stock's Price/Earning ratio is above 72% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACAD may be a overvalued for its sector.
The last closing price of ACAD's stock was USD 16.87.
The most recent market capitalization for ACAD is USD 3.00B.
Based on targets from 7 analysts, the average taret price for ACAD is projected at USD 26.96 over the next 12 months.
This means that ACAD's stock price may go up by +59.80% over the next 12 months.
We can't find any ETFs which contains ACADIA Pharmaceuticals Inc's stock.
As per our most recent records ACADIA Pharmaceuticals Inc has 620 Employees.
ACADIA Pharmaceuticals Inc's registered address is 12830 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from ACADIA Pharmaceuticals Inc's website at https://www.acadia.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ACADIA Pharmaceuticals Inc (ACAD) Stock
Based on ratings from 7 analysts ACADIA Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 8 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on ACAD's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ACAD is USD 26.96 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 20.
ACAD stock's Price/Earning ratio is 22.13.
Our analysis grades ACAD stock's Price / Earning ratio at F. This means that ACAD stock's Price/Earning ratio is above 72% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACAD may be a overvalued for its sector.
The last closing price of ACAD's stock was USD 16.87.
The most recent market capitalization for ACAD is USD 3.00B.
Based on targets from 7 analysts, the average taret price for ACAD is projected at USD 26.96 over the next 12 months.
This means that ACAD's stock price may go up by +59.80% over the next 12 months.
We can't find any ETFs which contains ACADIA Pharmaceuticals Inc's stock.
As per our most recent records ACADIA Pharmaceuticals Inc has 620 Employees.
ACADIA Pharmaceuticals Inc's registered address is 12830 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from ACADIA Pharmaceuticals Inc's website at https://www.acadia.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACAD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
